Seres Therapeutics, Inc.

MCRBNASDAQ • USD
ThemeBiotech - Drug Development›Infectious Disease & Vaccines
6.63 USD
↘ 0.22 (3.21%)AT CLOSE (11:59 AM EDT)
6.48
↘ 0.15 (2.26%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
6.48
↘ 0.15 (2.26%)
🔴Market: CLOSED
Open?$7.80
High?$7.80
Low?$6.32
Prev. Close?$6.85
Volume?280.9K
Avg. Volume?57.2K
VWAP?$6.95
Rel. Volume?4.91x
Bid / Ask
Bid?$6.33 × 400
Ask?$7.40 × 100
Spread?$1.07
Midpoint?$6.87
Valuation & Ratios
Market Cap?64.2M
Shares Out?9.7M
Float?6.6M
Float %?72.7%
P/E Ratio?N/A
P/B Ratio?2.42
EPS?-$4.84
Dividend?0.00%
Ex-Dividend?N/A

Seres Therapeutics, Inc. (MCRB) trades at $6.63 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place MCRB at a fair price relative to peers.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Themes
Biotech - Drug Development›Infectious Disease & Vaccines
Employees
66
Market Cap
64.2M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.serestherapeutics.com
Listed
2015-06-26
Address
200 SIDNEY STREET
CAMBRIDGE, MA 02139
Phone: 617 945 9626
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
18
Short Sent.?
33
Piotroski F-Score?0/9Weak
Altman Z-Score?-13.71Distress
Confidence?57%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?7.80%Elevated
Short Interest?512.8K
Days to Cover?11.1
Free Float6.6M
Avg Daily Volume46.3K
Settlement Date2026-05-15
Financial Health
Current Ratio?1.65Adequate
Quick Ratio?1.65Adequate
Cash Ratio?1.54Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
66
2.42CHEAP▾
P/S?
Peers
100
S&P
3
55.98HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.4CHEAP▾
EV/Sales?
Peers
100
S&P
3
29.97HIGH▾
Returns & Efficiency
ROE?
S&P
3
-177.0%WEAK▾
ROA?
S&P
3
-39.9%WEAK▾
Cash Flow & Enterprise
FCF?$-42371000
Enterprise Value?$34.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist